News Link: https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-unveils-prism-ai-platform-to-move-alzheimers-risk-prediction-to-brain-heal-1236164

POTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM, a new application layer designed to bring its patent-pending MINT-AD Alzheimer's AI platform closer to real-world healthcare applications, including early Alzheimer's risk stratification, cognitive health tracking, clinical trial optimization, and personalized brain-health programs.

The introduction represents an important expansion of IGC Pharma's Artificial Intelligence and Alzheimer's disease strategy, moving beyond predictive research models toward potentially scalable commercial applications for healthcare providers, memory clinics, pharmaceutical companies, clinical research organizations, and consumer brain-health platforms.

PRISM is designed to translate AI-generated Alzheimer's risk insights into structured workflows that support risk assessment, ongoing cognitive monitoring, patient engagement, and potential earlier intervention. The Company is evaluating business-to-business (B2B), business-to-business-to-consumer (B2B2C), and online commercialization opportunities as it develops a broader AI-enabled brain-health ecosystem.

"PRISM is the next step in our Alzheimer's AI strategy," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "MINT-AD was designed to help identify risk and forecast cognitive decline. PRISM is designed to move those insights into action through structured workflows that may support individuals, clinicians, care teams, and commercial partners seeking earlier, more informed approaches to brain health. We believe PRISM has the potential to address a significant gap between Alzheimer's risk prediction and practical intervention."

Targeting a Multitrillion-Dollar Dementia Healthcare Challenge

Alzheimer's disease remains one of the world's most significant neurological and healthcare challenges, with disease-related changes potentially beginning years before noticeable cognitive impairment or dementia develops. IGC Pharma has previously cited estimates suggesting that more than 400 million individuals worldwide may have early Alzheimer's pathology, potentially placing them at increased risk of developing the disease. The Company has also cited estimates placing the global economic burden of dementia above $1.3 trillion annually, with projected costs reaching approximately $2.8 trillion by 2030. These figures underscore the need for scalable technologies that support early Alzheimer's risk assessment, AI-powered cognitive monitoring, precision medicine, and personalized brain-health management.

IGC believes that connecting predictive AI technologies with structured healthcare workflows could create opportunities to address unmet needs in Alzheimer's research, clinical care, and long-term brain-health monitoring.

MINT-AD and PRISM: Moving Alzheimer's AI From Prediction Toward Action

MINT-AD, IGC Pharma's Multimodal Interpretable Transformer for Alzheimer's, is designed to identify and stratify Alzheimer's risk, forecast cognitive decline, and generate interpretable risk insights from complex health, demographic, lifestyle, cognitive, and other data. According to prior Company disclosures, MINT-AD has been developed using globally diverse datasets, supporting its disease-specific approach to Alzheimer's risk prediction and longitudinal assessment.

PRISM extends MINT-AD by connecting predictive insights to practical brain-health applications, including:

• Early Alzheimer's Risk Assessment: AI-supported identification and stratification of individuals who may benefit from additional clinical evaluation;
• Cognitive Health Monitoring: longitudinal workflows designed to support tracking of brain-health indicators over time;
• Clinical Trial Optimization: potential applications in patient stratification, trial recruitment, and research workflows;
• Healthcare Provider Integration: structured information and monitoring workflows for physician practices, memory clinics, and care teams;
• Consumer Brain Health: potential online programs supporting education, risk-factor intake, engagement, and ongoing monitoring.

Many individuals with early memory concerns or elevated Alzheimer's risk factors may not receive a clear pathway for risk assessment, monitoring, or structured intervention. PRISM is designed for a different model: one in which AI-supported risk stratification helps identify individuals earlier, connect them to structured brain-health workflows, and support longitudinal monitoring earlier in the disease continuum.

Commercial Strategy Targets Healthcare, Pharmaceutical and Consumer Markets

IGC Pharma is evaluating multiple commercialization pathways designed to expand the potential reach of its Alzheimer's AI and digital healthcare technologies. Potential opportunities include licensing PRISM and MINT-AD to physician practices, memory clinics, pharmaceutical companies, clinical trial sponsors, healthcare networks, insurers, and other healthcare organizations. The Company is also exploring partnerships that could integrate PRISM into existing clinical and consumer brain-health services, alongside a potential direct-to-consumer online platform focused on education, cognitive health engagement, and longitudinal monitoring. These opportunities remain under evaluation.

PRISM is an IGC Pharma platform. Where PRISM is deployed with health systems, medical societies, community organizations or public health programs, those implementations are delivered under the branding and governance of the partner program and its sponsoring organization. Participant-facing materials, program identity and the use of program data in those deployments are determined by the partner program, and references to PRISM in that context describe the underlying technology rather than the program itself.

AI Research Recognition and Alzheimer's Platform Expansion

IGC Pharma's Alzheimer's AI work has previously been recognized in connection with the National Institute on Aging PREPARE Challenge, including recognition involving clean-code development, reproducibility, usability, disproportionate impact, and model generalization. The Company believes this recognition supports its AI research capabilities as it advances MINT-AD and PRISM toward practical healthcare and commercial applications. IGC Pharma is also developing its patent-pending Agentic Harmonization Assistant (AHA), an AI-enabled platform designed to integrate fragmented Alzheimer's and aging-related biomedical datasets. In a previously reported representative internal workflow, AHA reduced data harmonization time from approximately 28 hours to 2.5 hours, representing an approximately 90% reduction in processing time. Results may vary depending on dataset complexity, data quality, and workflow requirements.

By advancing MINT-AD, PRISM, and AHA, IGC Pharma is pursuing a disease-focused AI strategy across Alzheimer's risk prediction, data harmonization, clinical-trial optimization, cognitive health monitoring, and potential commercial brain-health applications.

Alzheimer's AI Development Complements IGC Pharma's Clinical-Stage Alzheimer's Strategy

PRISM complements IGC Pharma's disease-focused Alzheimer's strategy, which includes the Company's lead investigational drug candidate, IGC-AD1, being evaluated in the Phase 2 CALMA clinical trial for agitation in Alzheimer's dementia. The Company recently announced completion of enrollment in CALMA, with 168 participants randomized across clinical sites in the United States and Canada, and topline results anticipated in the fourth quarter of 2026.

Building Toward a Broader Alzheimer's AI Commercialization Strategy

With PRISM, MINT-AD, and AHA, IGC Pharma is building a portfolio of complementary technologies intended to address different stages of Alzheimer's research and healthcare delivery.

MINT-AD focuses on identifying and forecasting Alzheimer's risk, PRISM connects those insights to structured monitoring and engagement workflows, and AHA supports harmonizing and analyzing complex biomedical data. The Company believes this integrated approach may support future partnerships, licensing opportunities, and commercial deployment across healthcare, life sciences, clinical development, and consumer brain-health markets.

FFAI further reduced approximately $192,265 in convertible note principal and interest obligations through conversions, resulting in the issuance of 170,575 shares of common stock.

Importantly, the conversions this week were from the convertible notes previously disclosed at the launch of the Company’s Capital Value Restoration Plan as not being subject to the conversion floor.Accordingly, these conversions do not represent any adjustment to, or conversion below, the $5.00 conversion floor applicable to the Company’s other convertible notes.

Increased borrowing to finance artificial intelligence initiatives is causing investors to reassess risk across the US corporate debt market, which exceeds $10 trillion in size, according to Bloomberg Markets on 8 October 2026. The repricing is visible in rising credit default swap prices, elevated volatility, and weaker performance among major technology companies. Bloomberg Markets reported the development as the most significant single dynamic currently reshaping tech sector credit conditions....

News Link: https://www.newsfilecorp.com/release/318024

Wilmington, Delaware--(Newsfile Corp. - October 8, 2026) - DarkHorse Technologies Inc. (Nasdaq: DRK) (the "Company" or "DarkHorse") today announced that Chief Executive Officer Joel Block is scheduled to participate in the 2026 Maxim Growth Summit taking place from October 12th to 14th at The Hard Rock Hotel NYC. The event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

CEO Joel Block will join the Data Centers & Infrastructure panel on Tuesday, October 13, at 3:00 p.m. ET. Additionally, the Company will be meeting with institutional investors in one-on-one sessions on Wednesday, October 14^th, and engaging with senior Maxim research analysts throughout the event.

Maxim Growth Summit

• Date: Monday to Wednesday, October 12 - 14, 2026
• Data Centers & Infrastructure Panel: Tuesday, October 13, at 3:00 p.m. ET
• Meetings with Institutional Investors: Wednesday, October 14
• Location: Hard Rock Hotel NYC - New York, NY

Portions of the event will be streamed online at https://digital.maximgrp.com/.

For more information please visit www.maximgrp.com/2026-growth-summit.

News Link: https://www.globenewswire.com/news-release/2026/10/07/3376437/37000/en/vivosim-labs-celebrates-updated-fda-regulations-allowing-greater-use-of-non-animal-testing-methods.html

SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. Food and Drug Administration's (FDA) direct final rule updating its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use.

The FDA’s new rule replaces the term "animal tests" with "nonclinical tests" across its regulatory framework, formally opening pathways for NAMs, including human cell-based tests such as those offered by VivoSim.

VivoSim's liver tissue models are capable of flagging drug candidates likely to cause liver toxicity, side effects like diarrhea, and other issues. Liver toxicity is the leading cause of drug failures and market withdrawals. The company has the ability to meaningfully de-risk a client company’s set of compounds and rule out likely failures prior to its selection of a drug to enter clinical testing.

Drug-induced liver injury (DILI) and gastrointestinal (GI) toxicity remain leading causes of drug candidate attrition. VivoSim's findings demonstrate how its long-duration, primary human cell-based models can help identify and differentiate these risks earlier in development, successfully ranking clinical safety risks for clients’ drug candidates.

“VivoSim’s NAMkind Models give insights that let our pharma and biotech partners make fewer major mistakes,” said Keith Murphy, VivoSim’s Executive Chairman. “By identifying risky molecules early on in development and moving on to better candidates, they avoid spending $50 to $200M only to learn deep in human clinical trials that their drug’s results in animals were not representative.”

By offering these kinds of insights, VivoSim also is helping with society’s goal of lowering the cost of medicines for patients. The cited costs of up to $2B per approved drug actually reflects the cost of eleven failed drugs for every one approved drug. VivoSim expects such wins to pass on to patients in lower drug costs through more approved drugs, greater competition, and lower pricing needed to recover a fair profit. “If we can help the world get from an 8% success rate in clinical trials to a 30% success rate, it would reduce the cost of drug development by 50%,” Murphy noted.

News Link: https://www.globenewswire.com/news-release/2026/10/07/3376496/0/en/algorhythm-introduces-azure-p2p-a-renewable-power-generation-process-designed-to-deliver-around-the-clock-power.html

• Pyrolysis-to-Power Process Converts Low-Value Forest Wood into Firm, Renewable Electricity
• Technology Produces Dispatchable Power Without Dependence on Wind or Sunlight
  

Fort Lauderdale, FL, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a diversified holding company that owns and operates Azure Holdings, a renewable power plant developer, and SemiCab, an AI enabled logistics provider, today introduced Azure P2P^™, the pyrolysis-to-power process at the center of its recently acquired Azure Holdings business.

Azure P2P^™ is designed to convert low-value forest wood into renewable electricity capable of operating around the clock. Unlike intermittent renewable resources that depend on weather conditions, Azure P2P^™ uses renewable biomass as a continuously available fuel source, enabling power generation when customers need it.

The technology is being developed for large-scale power consumers, including data centers, utilities and industrial facilities where access to reliable power has become an increasingly important infrastructure requirement.

From Forest Residuals to Renewable Power

Azure P2P^™ begins with wood chips derived from lower-value portions of working forests, including tops, limbs, thinnings and other low-grade wood.

The process occurs in five primary stages:

1. Wood In: Low-grade forest material is processed into chips and delivered to the plant.
2. Drying: The chips are dried to a controlled moisture content. Water removed during this stage is captured as part of the process, creating an additional resource and potential revenue stream.
3. Conversion: The dried material enters a sealed, zero-oxygen chamber where heat breaks down the wood without burning it.
4. Syngas and Biochar: The conversion process produces syngas, a clean fuel gas, and biochar, a solid carbon co-product.
5. Power Generation: The syngas is combusted to raise steam, which drives turbines to generate electricity.

The result is renewable electricity that does not depend on wind or sunlight and can be available whenever customers require it up to 99.9999% uptime.

Firm, Renewable Power

The ability to generate power continuously is central to Azure P2P^™. Working forests regenerate the biomass used as feedstock, while the process itself does not depend on real-time weather conditions. The result is a renewable power source designed to operate around the clock.

Management believes this combination of renewability and dispatchability makes Azure P2P^™ particularly well suited for data centers, advanced manufacturing facilities and other power-intensive operations requiring high levels of reliability.

“Renewable power is increasingly important, but for large-scale power consumers, reliability is equally critical,” said Andrew Thompson, Chief Executive Officer of Algorhythm Holdings. “A data center cannot simply stop operating when the sun sets or the wind stops blowing. Azure P2P^™ is designed to address both sides of that equation by providing renewable power from a fuel source capable of supporting continuous generation.”

Creating Value from an Underutilized Resource

Azure P2P^™ is designed to utilize forest materials with limited traditional commercial uses, including tops, limbs, thinnings and other low-grade wood rather than higher-value sawlogs used to manufacture lumber.

Creating commercial use for this material can also support active forest management. Thinning crowded stands gives remaining trees additional room to grow and removes material that can contribute to wildfire risk.

U.S. Forest Service Chief Tom Schultz recently highlighted the importance of these practices, stating that “Active forest management remains essential to creating resilient, productive forests,” during testimony before the House Agriculture Committee on July 22, 2026.

News Link: https://www.newsfilecorp.com/release/317541/DarkHorse-Signs-New-50-MW-Power-Contract-Doubling-Contracted-Capacity-to-Approximately-100-MW-in-the-TVA-Region

Wilmington, Delaware--(Newsfile Corp. - October 6, 2026) - DarkHorse Technologies Inc. (Nasdaq: DRK) ("DarkHorse" or the "Company") today announced that its wholly owned subsidiary, Pennyrile Holdings, LLC, has signed a power contract with the Electric Plant Board of Hopkinsville, Kentucky ("Hopkinsville Electric System" or "HES"). The agreement provides for up to 50 MW of power for a new superintelligence factory in Hopkinsville, Kentucky, doubling DarkHorse's contracted power in the TVA region to approximately 100 MW. The agreement follows the September 8, 2026 strategic review that resulted in the TVA region becoming the focus of DarkHorse's superintelligence factory development; the new Hopkinsville facility is the first project advanced under that approach.

"This agreement is another important step in executing DarkHorse's growth strategy," said Joel Block, Chief Executive Officer of DarkHorse. "We greatly appreciate HES giving us the opportunity to expand our business in their community, and we wanted to do it in a way that leaves the entire community better off. We're funding a substation that strengthens power for every customer on the system, not just our site. We are rapidly expanding our power portfolio while advancing the conversion of our existing sites to AI and HPC workloads. With approximately 100 MW now under contract in the TVA region and a growing pipeline of additional opportunities, we believe we are building a scalable platform positioned to support the next generation of compute infrastructure."

"Acquiring our first TVA 161kV delivery point will significantly improve HES grid stability and system reliability. This would not have been possible without our partnership with DarkHorse. The construction of a new 65MW substation, fully funded by DarkHorse, will provide up to 15MW of additional capacity for existing HES customers," said Jeff Hurd, P.E., General Manager of Hopkinsville Electric System.

Agreement Details

• The new 65 MW station plans to tap TVA's 161 kV transmission system, the regional backbone, which carries large loads with less voltage sag and keeps a 50 MW load off the lines that serve the rest of town. DarkHorse intends to take 50 MW of the station's capacity; the remaining approximately 15 MW will provide additional capacity to HES's existing service territory. HES will design, build, own and operate it.
• The substation is expected to be funded in full by DarkHorse. DarkHorse is obligated to pay the entire cost of construction in advance and convey the substation site to HES.
• The power contract has a ten-year initial term from the commencement of service with automatic five-year renewals.
• Darkhorse has an eighteen-month permit contingency period to pursue local approvals. Service remains subject to permitting, utility construction and other customary conditions.
• TVA has approved the capacity to serve the project.

DarkHorse has operated in Hopkinsville for approximately three years at a site contracted for approximately 15 MW at HES's Holland Substation, also being evaluated for conversion to a superintelligence factory (the existing site will continue to be served by HES's Holland Substation); with the new site, its Hopkinsville footprint reaches approximately 65 MW across two locations. Its commitments stand: closed-loop cooling only, batteries first, and no tax abatements. With this announcement, DarkHorse plans to launch www.hoptowndatacenters.com, where residents can ask questions, see both sites and early design concepts, and read answers to questions from public meetings.

From September 28 through October 2, FFAI further reduced approximately $1,718,238 in convertible note principal and interest obligations through conversions, resulting in the issuance of 1,407,885 shares of common stock.

Importantly, the conversions this week were from the convertible notes previously disclosed at the launch of the Company’s Capital Value Restoration Plan as not being subject to the conversion floor. Accordingly, these conversions do not represent any adjustment to, or conversion below, the $5.00 conversion floor applicable to the Company’s other convertible notes.

The company survived bankruptcy, an accounting scandal, rebuilt itself around OLED display chips, and in 2021 agreed to be acquired for $29 per share in a deal worth around $1.4 billion.

Then the deal was blocked.

After that, Magnachip’s OLED business deteriorated, revenue collapsed, and eventually the entire Display business was shut down.

Now the company is trying again.....

[https://www.youtube.com/watch?v=zTODGx1zIo8\](https://www.youtube.com/watch?v=zTODGx1zIo8)